Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug;11(8):1877-1878.
doi: 10.1158/2159-8290.CD-21-0613.

Impaired CD4 T-cell Response to SARS-CoV-2: Rationale for PD-1 Blockade in Patients with Cancer and COVID-19?

Bérengère Salomé  1 , Amir Horowitz  2
Affiliations
Comment

Impaired CD4 T-cell Response to SARS-CoV-2: Rationale for PD-1 Blockade in Patients with Cancer and COVID-19?

Bérengère Salomé et al. Cancer Discov. 2021 Aug.

Abstract

Cancer is a strong risk factor for severe COVID-19 disease. In this issue of Cancer Discovery, Bilich and colleagues demonstrate impaired preexisting and newly generated CD4 T-cell response to SARS-CoV-2 in patients with cancer.See related article by Bilich et al., p. 1982.

PubMed Disclaimer

Comment in

  • Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer.
    Bilich T, Roerden M, Maringer Y, Nelde A, Heitmann JS, Dubbelaar ML, Peter A, Hörber S, Bauer J, Rieth J, Wacker M, Berner F, Flatz L, Held S, Brossart P, Märklin M, Wagner P, Erne E, Klein R, Rammensee HG, Salih HR, Walz JS. Bilich T, et al. Cancer Discov. 2021 Aug;11(8):1982-1995. doi: 10.1158/2159-8290.CD-21-0191. Epub 2021 May 19. Cancer Discov. 2021. PMID: 34011563

Comment on

  • Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer.
    Bilich T, Roerden M, Maringer Y, Nelde A, Heitmann JS, Dubbelaar ML, Peter A, Hörber S, Bauer J, Rieth J, Wacker M, Berner F, Flatz L, Held S, Brossart P, Märklin M, Wagner P, Erne E, Klein R, Rammensee HG, Salih HR, Walz JS. Bilich T, et al. Cancer Discov. 2021 Aug;11(8):1982-1995. doi: 10.1158/2159-8290.CD-21-0191. Epub 2021 May 19. Cancer Discov. 2021. PMID: 34011563

References

    1. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–91.
    1. Sattler A, Angermair S, Stockmann H, Heim KM, Khadzhynov D, Treskatsch S, et al. SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition. J Clin Invest. 2020;130:6477–89.
    1. Loyal L, Braun J, Henze L, Kruse B, Dingeldey M, Reimer U, et al. Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. MedRxiv. 2021.
    1. Bilich T, Roerden M, Maringer Y, Nelde A, Heitmann JS, Dubbelaar ML, et al. Preexisting and post–COVID-19 immune responses to SARS-CoV-2 in patients with cancer. Cancer Discov. 2021;11:1982–95.
    1. Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33:547–62.

Publication types

Substances